Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis

• Main Authors: Jianzhou Yan (Author), Caiyun Li (Author), Xuefang Zhang (Author), Luyan Cheng (Author), Ruilin Ding (Author), Lingli Zhang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ObjectiveTo explore the cost-effectiveness of degarelix acetate for injection (degarelix) compared to leuprorelin in prostate cancer (Pca) castration treatment from Chinese healthcare system perspective.MethodsA Markov model, adapted from the one established in Finland was conducted for the cost-eff...